Cryo-Cell International Inc(CCEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 6:54 PM ET (Korea 9/12 07:54)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.31 | Insider Own | 47.86% | Shs Outstand | 8.1M | Perf Week | 3.77% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.2M | Perf Month | 13.4% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 13.72% | Short Float | 0.13% | Perf Quarter | 21.16% |
| Income | -0.00B | P/S | 1.14 | EPS this Y | - | Inst Trans | 1.94% | Short Ratio | 0.25 | Perf Half Y | 41.48% |
| Sales | 0.03B | P/B | - | EPS next 5Y | - | ROA | -3.94% | Short Interest | 0.01M | Perf YTD | 27.91% |
| Book/sh | -2.2 | P/C | 11.23 | EPS past 3/5Y | - | ROE | - | 52W High | -12.09% ($5.01) | Perf Year | -5.78% |
| Cash/sh | 0.39 | P/FCF | 5.81 | Sales past 3/5Y | 1.33% 0.27% | ROIC | - | 52W Low | 61.76% ($2.72) | Perf 3Y | -24.79% |
| Dividend Est. | - | EV/EBITDA | 32.5 | EPS Y/Y TTM | -1365.07% | Gross Margin | 75.56% | Volatility(W/M) | 5.48% 8.74% | Perf 5Y | -61.42% |
| Dividend TTM | - | EV/Sales | 1.33 | Sales Y/Y TTM | -2.69% | Oper. Margin | -0.33% | ATR (14) | 0.31 | Perf 10Y | 25.3% |
| Dividend Ex-Date | 2025/5/21 | Quick Ratio | 0.69 | EPS Q/Q | 57.08% | Profit Margin | -7.92% | RSI (14) | 61.01 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.71 | Sales Q/Q | -1.93% | SMA20 | 5.54% ($4.17) | Beta | 0.49 | Target Price | $8.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/7/15 | SMA50 | 16.63% ($3.77) | Rel Volume | 0.9 | Prev Close | $4.12 |
| Employees | 76 | LT Debt/Eq | - | EPS/Sales Surpr. | - 3.27% | SMA200 | 22.88% ($3.58) | Avg Volume(3M) | 0.02M | Price | $4.4 |
| IPO | 1994/4/4 | Option/Short | No/Yes | Trades | 199 | Volume | 20,760 | Change | 6.8% |
Company
CCEL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Cryo-Cell International is the world's first private cord blood bank—a U.S. healthcare company that provides family-based long-term storage of stem cells collected from newborns' umbilical cord blood and cord tissue. It is a small-cap company listed on Nasdaq and generates stable recurring revenue through a combination of new-contract fees and annual storage fees. Since its founding in 1989, it has been a traditional niche company that has consistently remained profitable.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
CCEL has weak earning power
Review management risk carefully before investing
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -24.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 13.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $35M.
CCEL $35M PER -
HCA $92B PER 14.3
THC $21B PER 10.2
EHC $12B PER 19.8
FAQ
What kind of company is CCEL?
CCEL belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of CCEL?
The market cap of CCEL is approximately $35M, ranking 5,084 within its sector.
What is the 52-week high and low for CCEL?
CCEL has recorded a 52-week high of $5.01 and a low of $2.72.
